

January 6, 2022  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Joint research agreement to establish a Social Collaboration Course,  
Molecular Oncology, with the University of Tokyo**

TOKYO, Japan, January 6, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today that it has entered into a joint research agreement (the "Agreement") with the University of Tokyo to establish a Social Collaboration Course, Molecular Oncology, and to explore the underlying molecular mechanisms of anti-tumor drug therapies using bendamustine and rigosertib, which are under development by SymBio as anticancer drugs.

Under the Agreement, SymBio will establish a Social Collaboration Course, Molecular Oncology (beginning on April 1, 2022) at the Graduate School of Pharmaceutical Sciences at the University of Tokyo, and conduct research in collaboration with Professor Shohei Hori, Graduate School of Pharmaceutical Sciences, and Professor Toshio Kitamura and Associate Professor Enomoto Yutaka, Institute of Medical Sciences. Under the research collaboration, various tumor cells and evaluation systems will be used, and epigenetic control and the cancer immune system will be explored to analyze the pharmacological effects of bendamustine and rigosertib, alone or in combination with other drugs, toward the development of new indications for the compounds.

Professor Hori has achieved outstanding research work in elucidating the molecular mechanisms involved in regulatory T cell function opening up a new research paradigm. Professor Kitamura made significant achievements in the research of hematopoietic tumors such as leukemia and the differentiation of hematopoietic stem cells and established an extensive network in his field. He is currently working to elucidate the molecular mechanisms during the development of hematopoietic tumors caused by epigenetic abnormalities and developing novel therapies using hematopoietic tumor models.

Statement of Fuminori Yoshida, President and Chief Executive Officer of SymBio: "This joint research seeks to maximize business value through use of a more multifaceted approach from the molecular mechanism level to explore further potential benefits of bendamustine and rigosertib, either alone or in combination with each other or other drugs, in order to develop new therapeutic methods".

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2021.

## [Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

## About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion, freeze-dried (FD) formulation, was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- TREAKISYM® ready-to-dilute (RTD) liquid formulation was approved in Japan in September 2020 for all the above indications.
- TREAKISYM® FD and RTD were approved for the additional indication of relapsed or refractory DLBCL in March 2021 and April 2021, respectively.

## About rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July, 2011 for Japan and Korea.

## About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to address underserved medical needs.